Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Organisation › Details

Immunic AG

Immunic AG is a start-up biotech company founded in April 2016 and focused on the development of immune modulators to block TH17- and TH1-mediated immune and autoimmune responses. The company’s two development programs include orally available, small molecule inhibitors of DHODH (IMU-838 program) and RORgt (IMU-366 program) relevant to diseases such as Crohn’s disease and psoriasis. The final aim is to develop these drug candidates to clinical proof of concept. Immunic, with headquarters in Planegg-Martinsried near Munich, Germany, is privately held and supported by several renowned sector investors. *

 

Period Start 2016-04-12 established
Products Industry small-molecule drug
  Industry 2 immunotherapy
Persons Person Vitt, Daniel (Immunic 201701– CEO before 4SC 1997–201612 CSO + Co-Founder before Univ Würzburg)
  Person 2 Gröppel, Manfred (Immunic 201604– COO + Co-Founder before 4SC 200901 Business Development)
     
Region Region Martinsried
  Country Germany
  Street 19a Am Klopferspitz
  City 82152 Martinsried
  Tel +49-89-700763-0
    Address record changed: 2016-10-01
     
Basic data Employees A: 1 to 10 (2018-12-20)
     
    * Document for �About Section�: Immunic AG. (9/28/16). "Press Release: Immunic Acquires 4SC’s Immunology Portfolio". Planegg-Martinsried.
     
   
Record changed: 2019-01-18

Advertisement

Picture [iito] – Putting Information into Context 600x60px

More documents for Immunic AG


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top